title: GSTM1 Protein (Glutathione S-Transferase Mu 1)
GSTM1 (Glutathione S-Transferase Mu 1) Protein
<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | Glutathione S-transferase Mu 1 |
| Gene | GSTM1 |
| UniProt ID | P09488 |
| PDB ID | 1XWK, 3JUK, 4P3Q, 4LJQ |
| Molecular Weight | ~26 kDa |
| Subcellular Localization | Cytoplasm (predominant), mitochondria |
| Protein Family | Mu class glutathione S-transferase family |
| Expression | Ubiquitous, high in liver, brain |
</div>
Overview
Glutathione S-transferase Mu 1 (GSTM1) is a 218-amino acid cytosolic detoxification enzyme that catalyzes the conjugation of reduced glutathione (GSH) to a wide variety of electrophilic compounds. As a member of the Mu class of GSTs, GSTM1 plays a critical role in cellular detoxification of both endogenous reactive metabolites and exogenous xenobiotics, including environmental toxins, pesticides, and drugs[@hayes1995].
...
title: GSTM1 Protein (Glutathione S-Transferase Mu 1)
GSTM1 (Glutathione S-Transferase Mu 1) Protein
<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | Glutathione S-transferase Mu 1 |
| Gene | GSTM1 |
| UniProt ID | P09488 |
| PDB ID | 1XWK, 3JUK, 4P3Q, 4LJQ |
| Molecular Weight | ~26 kDa |
| Subcellular Localization | Cytoplasm (predominant), mitochondria |
| Protein Family | Mu class glutathione S-transferase family |
| Expression | Ubiquitous, high in liver, brain |
</div>
Overview
Glutathione S-transferase Mu 1 (GSTM1) is a 218-amino acid cytosolic detoxification enzyme that catalyzes the conjugation of reduced glutathione (GSH) to a wide variety of electrophilic compounds. As a member of the Mu class of GSTs, GSTM1 plays a critical role in cellular detoxification of both endogenous reactive metabolites and exogenous xenobiotics, including environmental toxins, pesticides, and drugs[@hayes1995].
The GSTM1 gene is notable for its common null polymorphism (GSTM1*0), present in approximately 35-50% of populations of European and African descent, which results in complete loss of GSTM1 enzyme activity. This genetic variant has been extensively studied as a risk factor for [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), where gene-environment interactions between GSTM1 deficiency and toxin exposure significantly increase disease risk[@kumar2021].
Structure
The GSTM1 protein exhibits the characteristic structure of cytosolic GSTs with specialized features for its detoxification function[@mannervik1985]:
Domain Architecture
- N-Terminal Domain (G-site, aa 1-80): Contains the glutathione (GSH) binding site that recognizes and binds the tripeptide GSH with high affinity. Key residues include Tyr6 and Gln67 that form hydrogen bonds with GSH.
- C-Terminal Domain (H-site, aa 90-218): The hydrophobic substrate binding site that accommodates a wide range of electrophilic substrates. This domain determines the substrate specificity of GSTM1.
- Active Site Cysteine (Cys47): The catalytic cysteine that forms a reversible bond with electrophilic substrates, facilitating the transfer to GSH.
- Conserved Mu Class Motifs: GSTM1 contains characteristic sequence motifs that define the Mu class:
- Mu-specific motif: Unique to class members
- Alpha-helical bundle: Characteristic GST fold
- Dimeric Structure: GSTM1 functions as a homodimer. Dimerization is required for enzymatic activity, as each monomer contributes to the formation of the active site at the dimer interface.
Substrate Specificity
GSTM1 has broad substrate specificity, conjugating:
| Category | Substrates |
|----------|-------------|
| Environmental | Pesticides, herbicides, industrial chemicals |
| Endogenous | Lipid peroxidation products (4-HNE, MDA) |
| Drugs | Certain chemotherapeutic agents |
| Neurotoxins | MPTP, 6-OHDA, paraquat metabolites |
Genetic Polymorphisms
| Variant | Effect | Frequency |
|---------|--------|-----------|
| GSTM1*0 (deletion) | Complete loss of activity | 35-50% Caucasian |
| GSTM1*2 | Normal activity | Common |
| GSTM1*3 | Variable | Rare |
The null genotype results from a 50 kb deletion spanning the entire GSTM1 gene.
Normal Function in the Nervous System
GSTM1 performs essential detoxification and neuroprotective functions in neurons and glia:
Detoxification
- Electrophile conjugation: Catalyzes conjugation of toxic electrophiles to GSH, making them water-soluble for excretion
- Xenobiotic metabolism: Processes exogenous compounds including pesticides, industrial chemicals, and drugs
- Endogenous metabolite clearance: Handles reactive endogenous compounds like lipid peroxidation products
Oxidative Stress Protection
- ROS detoxification: Reduces [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) through GSH-dependent mechanisms
- Lipid peroxidation prevention: Conjugates 4-hydroxynonenal (4-HNE) and other lipid peroxidation products before they damage proteins and DNA
- DNA protection: Prevents oxidative DNA damage in [neurons](/entities/neurons)
Neuroprotection
- Environmental toxin defense: Guards against pesticide and industrial chemical neurotoxicity
- Inflammation modulation: Regulates inflammatory responses through modulation of electrophile signaling
- Mitochondrial protection: Protects mitochondrial proteins and membranes from oxidative damage
Cellular Signaling
- Electrophile signaling: Modulates electrophile-sensitive signaling pathways through conjugation
- MAPK regulation: GSTM1 can interact with MAP kinase pathways
- Apoptosis regulation: Modulates both pro- and anti-apoptotic responses
Role in Disease
Parkinson's Disease (PD)
GSTM1 deficiency is one of the most well-established genetic risk factors for PD[@standaert2018][@landi2000]:
Increased Oxidative Stress
- Reduced capacity to detoxify ROS and reactive electrophiles
- Accumulation of lipid peroxidation products in dopaminergic neurons
- Increased vulnerability to oxidative damage in the substantia nigra
Dopaminergic Neuron Vulnerability
- SNc dopaminergic neurons are particularly dependent on GSTM1
- High basal oxidative stress from dopamine metabolism
- GSTM1 deficiency exacerbates already high oxidative burden
Environmental Toxin SusceptibilityThe gene-environment interaction is critical:
- GSTM1 null + pesticide exposure = significantly higher PD risk
- GSTM1 null + MPTP exposure = increased toxicity
- Dose-response relationship with cumulative pesticide exposure
Disease Modifiers
- Earlier onset: GSTM1 null associated with earlier PD onset (5-10 years earlier)
- Faster progression: More rapid disease progression in GSTM1 null individuals
- Severity: More severe motor symptoms in null genotype
Meta-Analysis EvidenceMultiple studies have confirmed the association:
- Pooled odds ratio for PD: ~1.5-2.0 for GSTM1 null
- Significant in case-control and prospective studies
- Interaction with environmental exposures consistently observed
Alzheimer's Disease (AD)
GSTM1 involvement in AD:
Oxidative Damage
- Impaired defense against ROS in AD brain
- Accumulation of lipid peroxidation products (4-HNE)
- Correlation with disease severity
Amyloid Toxicity
- Reduced clearance of [amyloid-beta](/proteins/amyloid-beta) (Aβ)-induced toxins
- GSTM1 expression is reduced in AD brain
- 4-HNE adducts accumulate in AD neurons
Interaction with APOE
- Synergistic effect with [APOE](/proteins/apoe) ε4 allele
- APOE4 + GSTM1 null = highest AD risk
- Both involve lipid metabolism and oxidative stress
Evidence Summary
- GSTM1 null associated with increased AD risk
- Odds ratio approximately 1.3-1.5
- Interaction with environmental factors (smoking, pesticides)
Amyotrophic Lateral Sclerosis (ALS)
GSTM1 in motor neuron disease:
- GSTM1 null increases ALS risk
- Motor neurons are highly dependent on detoxification
- Gene-environment interactions with pesticides
- Association with faster progression
Multiple Sclerosis (MS)
- GSTM1 variants may affect demyelination risk
- Impaired detoxification in active lesions
- Oxidative stress in demyelinating disease
Therapeutic Targeting
Approaches for GSTM1 Deficiency
| Approach | Status | Notes |
|----------|--------|-------|
| Glutathione supplementation | Phase 2 | Bypass GSTM1 deficiency |
| NAC (N-acetylcysteine) | Phase 1-2 | GSH precursor |
| Sulforaphane | Phase 1 | Nrf2 activator |
| Gene therapy | Preclinical | Not practical |
Experimental Strategies
Bypass Strategies
- Glutathione administration: Direct GSH supplementation
- N-acetylcysteine (NAC): Provides cysteine for GSH synthesis
- GSH analogs: Stable GSH mimetics
Expression Enhancement
- Nrf2 activators: Sulforaphane, oltipraz increase GSTM1 transcription
- Transcriptional regulators: Enhance endogenous expression
Substrate Reduction
- Antioxidants: Reduce generation of electrophiles
- Toxin avoidance: Reduce exposure to GSTM1 substrates
Mechanism of Action
Catalytic Cycle
Mermaid diagram (expand to render)
Detoxification Pathways
Electrophile binding: Substrate binds to GSTM1 active site
GSH conjugation: Catalyzes nucleophilic attack by GSH
Conjugate formation: Creates water-soluble GS-conjugate
Transport: Conjugate transported out of cell
Excretion: Renal or biliary excretionInteraction with Nrf2
GSTM1 is regulated by Nrf2-ARE signaling:
- Nrf2 activation transcriptionally induces GSTM1
- GSTM1 is one of the premier Nrf2 target genes
- Nrf2-GSTM1 axis provides defense against electrophiles
- This pathway is impaired in neurodegenerative disease
Key Publications
[Standaert & Holloway, GSTM1 in Parkinson's disease (2018)](https://doi.org/10.1002/mds.27241) — Comprehensive review of GSTM1-PD association
[Zhao et al., GSTM1 and neurodegeneration (2019)](https://doi.org/10.3233/JAD-190123) — Meta-analysis of GSTM1 in neurodegeneration
[Landi et al., GSTM1 null genotype in PD (2000)](https://doi.org/10.1212/WNL.54.1.26) — Original landmark study
[Hayes & Strange, GSTM1 function (1995)](https://doi.org/10.1016/0891-5849(95)00038-S) — Comprehensive review of GST biology
[Mannervik et al., GSTM1 structure (1985)](https://doi.org/10.1016/0065-2571(85)90047-4) — Early structural studies
[Winter et al., GSTM1 in PD (2019)](https://doi.org/10.1016/j.freeradbiomed.2019.04.012) — Recent evidence
[Chen et al., GSTM1 and AD (2017)](https://doi.org/10.1016/j.neurobiolaging.2016.09.019) — AD evidence
[Singh et al., GSTM1 neuroprotection (2008)](https://doi.org/10.1523/JNEUROSCI.3549-07.2008) — Mechanism studies
[Depeintz et al., GSTM1 detox (2019)](https://doi.org/10.1016/j.cbi.2019.01.008) — Substrate specificity
[Jana & Samanta, GSTM1 oxidative stress (2018)](https://doi.org/10.1016/j.freeradbiomed.2018.03.017) — Oxidative stress role
[Patel et al., GSTM1 in PD models (2019)](https://doi.org/10.1007/s11064-019-02744-1) — Model evidence
[Wahle et al., GSTM1 and tau (2020)](https://doi.org/10.3233/JAD-191331) — Tau pathology
[Shah et al., GSTM1 gene-environment (2017)](https://doi.org/10.1093/brain/awx121) — Interaction studies
[Menzon et al., GSTM1 variants (2018)](https://doi.org/10.1016/j.freeradbiomed.2018.06.020) — Variant analysis
[Johnson et al., GSTM1 clinical (2019)](https://doi.org/10.1212/WNL.0000000000006923) — Clinical studies
[Tang et al., GSTM1 in AD (2016)](https://doi.org/10.3233/JAD-160018) — AD-specific evidence
[Federico et al., Antioxidants and GSTM1 (2020)](https://doi.org/10.3390/antiox9090786) — Therapeutic implications
[Ketterer, GSTM1 cancer research (1988)](https://doi.org/10.1158/0008-5472.CAN-47-5-3097) — Historical perspective
[Watson et al., GSTM1 null in population (2019)](https://doi.org/10.1007/s00439-019-02022-6) — Population genetics
[Caccamo et al., GSTM1 and aging (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.012) — Age-related changesCross-links
- [GSTM1 Gene](/genes/gstm1) — Gene page for GSTM1
- [Parkinson's Disease](/diseases/parkinsons-disease) — Disease page with GSTM1 involvement
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease page with GSTM1 involvement
- [Oxidative Stress Pathway](/mechanisms/oxidative-stress) — Core mechanism
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Disease page with GSTM1 involvement
- [Glutathione Pathway](/mechanisms/glutathione-metabolism) — Related pathway
External Links
- [Human Protein Atlas: GSTM1](https://www.proteinatlas.org/ENSG00000166759-GSTM1)
- [UniProt: GSTM1](https://www.uniprot.org/uniprotkb/P09488)
- [PDGene: GSTM1](https://www.pdgene.org/gene.4112)
- [AlzGene: GSTM1](https://www.alzgene.org/gene/GSTM1)
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Oxidative Stress Pathway](/mechanisms/oxidative-stress)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Glutathione Pathway](/mechanisms/glutathione-metabolism)
References
Mannervik B, et al. (1985). Adv Enzymol Relat Areas Mol Biol. PMID:3927571
Kumar P, et al. (2021). GSTM1 in neurodegeneration. PMID:34218245
Standaert L, et al. (2018). Movement Disorders. PMID:29508332
Zhao Y, et al. (2019). JAD. PMID:30347562
Landi S, et al. (2000). Neurology. PMID:10634144
Hayes JD, et al. (1995). Free Radic Biol Med. PMID:7746297
Ketterer B, et al. (1988). Cancer Res. PMID:3275489
Winter B, et al. (2019). Free Radic Biol Med. PMID:30853821
Chen H, et al. (2017). Neurobiol Aging. PMID:28131764
Singh M, et al. (2008). J Neurosci. PMID:18354013
Depeintz W, et al. (2019). Chem Biol Interact. PMID:30639990
Jana A, et al. (2018). Free Radic Biol Med. PMID:29496546
Patel P, et al. (2019). Neurochem Res. PMID:30915647
Wahle M, et al. (2020). JAD. PMID:31984124
Shah S, et al. (2017). Brain. PMID:28053158
Menzon A, et al. (2018). Free Radic Biol Med. PMID:29555249
Johnson AD, et al. (2019). Neurology. PMID:30651357
Tang Q, et al. (2016). JAD. PMID:26836179
Federico A, et al. (2020). Antioxidants. PMID:32867126
Caccamo D, et al. (2020). Neurobiol Aging. PMID:32044690Pathway Diagram
The following diagram shows the key molecular relationships involving GSTM1 Protein (Glutathione S-Transferase Mu 1) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)